Boston Scientific has wrapped up the previously announced $1.07 billion acquisition of the global surgical business of Israeli medical solutions provider Lumenis.

The US medical device manufacturer had signed the deal in March 2021 with an affiliate of Baring Private Equity Asia (BPEA), which owns Lumenis. The BPEA affiliate will retain ownership of Lumenis’ global aesthetics and ophthalmology businesses.

The surgical business acquired by Boston Scientific includes premier laser systems, fibers and accessories. These are used for urology and otolaryngology procedures.

The business is expected to post total revenue of around $200 million for the full year 2021.

Boston Scientific plans to sell the lasers and fibers along with the otolaryngology laser portfolio to all countries, including China.

Meghan Scanlon — senior vice president and president of Boston Scientific Urology and Pelvic Health said: “The close of this acquisition allows us to integrate the Lumenis laser portfolio – including the differentiated MOSES technology – with our category leading kidney stone management and benign prostatic hyperplasia offerings while expanding our global footprint to accelerate growth throughout Europe and Asia.

“Additionally, we are welcoming significant talent to our Urology & Pelvic Health Team, and we are excited to establish our global surgical laser center of excellence in Yokneam where we will continue our focus on advancing innovation to help surgeons improve patient care.”

  Baring Private Equity Asia, Boston Scientific, Israel, Lumenis, medical device industry news, Meghan Scanlon